Exact Sciences Corp (($EXAS)) announced an update on their ongoing clinical study. Exact Sciences Corp is currently recruiting participants for ...

Heal Squad' podcast host Maria Menounos, whose pancreatic cancer was discovered early enough to be treated, says, "If it ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a biotechnology company pioneering an early cancer ...

According to Cologuard, made by Wisconsin-based Exact Sciences, there are three primary reasons why you may receive a testing ...

Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) blood test that is now available as ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance ...

Exact Sciences Corp (($EXAS)) announced an update on their ongoing clinical study. Study Overview: The EXActDNA-003 / NSABP B-64 study, officially ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) test has received Medicare ...

Exact Sciences’ research at ACG 2025 underscores our leadership in advancing evidence-based, patient-centered screening solutions that improve adherence and outcomes,” said Paul Limburg, MD, MPH, AGAF ...

Nearly 70 percent of annual cancer cases and deaths in the U.S. occur in cancers with no recommended screening.1,2,3 The Cancerguard test can help address the unmet need by complementing existing ...